Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RaPiDS
NCT03894215Phase 2Terminated
- Sponsor
- Agenus Inc.
- Start
- Jun 2019
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Cervical Cancer (CC) comparing AGEN2034 + Placebo with AGEN2034 + AGEN1884 (2 arms). Primary endpoint: Objective Response Rate at 48 months. Started Jun 2019; status: terminated.
02
Drugs
balstilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03894215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894215.